Intravenous immunoglobulins control scleromyxoedema.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 11779761.
- Also identified by PMC identifier 1753886.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Scleromyxoedema is a variant of papular mucinosis affecting the skin and internal organs. The different therapeutic approaches proposed for scleromyxoedema are still unsatisfactory. Intravenous immunoglobulin (IVIg) has been successfully employed in the treatment of connective tissue diseases and vasculitides. The successful treatment of three cases of scleromyxoedema with IVIg is reported here. The relatively low risk of the drug and the high effectiveness seen in three patients suggest that IVIg is a new treatment potentially useful in scleromyxoedema.
Medical subject headings
- Immunoglobulins, Intravenous
- Myxedema